Genmab — Juni 2013
-
-
Sidste sætning er nyt for mig Further studies: We are currently exploring an 8 mg/kg weekly schedule but will
also explore other doses and different schedules Ellers er det vidst den samme vin på ny flaske -
Apropos Hazard Ratio: Udregnes i GA101 studiet
som "reduction i risiko for progression eller død" Der står ikke noget om til hvilket tidspunkt. -
-
http://finance.yahoo.com/news/updated-results-two-phase-2-100000078.html Ibrutinib er en voldsom modstander for Arzerra.
-
stærke data må man sige
-
-
For mig handler det bare om at Arzerra bliver fremtidens golden standard som kombi med Ibrutinib
-
istedet for Rituxan eller GA101
-
For jeg tror ikke der er tvivl om at det er Ibrutinib der bliver det helt store
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind